X T L Biopharmaceuticals traded at $2.71 this Wednesday March 25th, increasing $0.10 or 3.75 percent since the previous trading session. Looking back, over the last four weeks, X T L Biopharmaceuticals gained 255.92 percent. Over the last 12 months, its price rose by 146.36 percent. Looking ahead, we forecast X T L Biopharmaceuticals to be priced at 2.63 by the end of this quarter and at 2.41 in one year, according to Trading Economics global macro models projections and analysts expectations.
XTL Biopharmaceuticals Ltd is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). hCDR1 is a peptide (short protein) that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.